Business context and reporting period
The filing is PerkinElmer, Inc.’s Form 10-K for the fiscal year ended January 1, 2017, not a filing under the name Revvity, Inc. Fiscal 2016 comprised 52 weeks; fiscal 2015 comprised 53 weeks, which affects year-over-year comparisons. The company reorganized into Discovery & Analytical Solutions and Diagnostics in the fourth quarter, and retrospectively recast prior-period segment data. Medical Imaging was classified as discontinued operations because its sale was pending.
PerkinElmer supplies products and services for diagnostics, environmental, food, industrial, life sciences research and laboratory services markets. Approximately 60% of fiscal 2016 sales came from international operations.
Financial results and key metrics
- Revenue: Continuing-operations revenue was $2.116 billion, up $10.7 million, or 1%, from $2.105 billion. Product revenue was $1.397 billion and service revenue was $718.6 million.
- Profit: Operating income from continuing operations was $283.1 million, versus $250.9 million. Income from continuing operations was $215.7 million, versus $188.8 million; net income, including discontinued operations, was $234.3 million, versus $212.4 million. Diluted EPS was $1.96 from continuing operations and $2.12 total.
- Margins: Gross margin improved to 47.9% from 45.8%, and operating margin to approximately 13.4% from 11.9%. Management attributed improvement primarily to product mix, supply-chain initiatives and cost controls.
- Segments: Discovery & Analytical Solutions revenue was $1.513 billion, down 1%, with operating income of $207.5 million. Diagnostics revenue was $602.5 million, up 5%, with operating income of $138.9 million.
- Cash flow and investment: Continuing-operations operating cash flow was $323.8 million, compared with $263.8 million. Capital expenditures were $31.7 million; acquisitions used $71.9 million net cash. Cash and cash equivalents ended at $359.3 million.
- Debt and liquidity: Balance-sheet debt was approximately $1.046 billion, including $495.8 million of 5% notes due 2021, $517.8 million of 1.875% euro-denominated notes due 2026, and $37.1 million of financing lease obligations. The $1.0 billion revolving facility had no borrowings and $988.6 million available. Most cash, $348.5 million, was held outside the U.S.; the filing says approximately $322.5 million could incur U.S. tax if transferred without planning.
- Shareholder returns: The company repurchased 3.2 million shares for $148.2 million under the prior program and paid $30.8 million in dividends. The declared annual dividend was $0.28 per share.
Fourth-quarter snapshot: Revenue was $566.8 million, gross profit $276.2 million, operating income from continuing operations $80.4 million, continuing-operations income $62.3 million and net income $64.8 million. Diluted EPS was $0.59 total. The quarter included a $15.3 million pre-tax postretirement-benefit mark-to-market loss.
Material changes versus the prior comparable period
- Revenue rose only 1% despite a favorable reported comparison; fiscal 2015 had an extra week, and foreign exchange reduced fiscal 2016 revenue by approximately 1%.
- Diagnostics grew 5%, led by newborn and infectious-disease screening, particularly in China and Europe. Discovery & Analytical Solutions declined 1%: weaker environmental and food demand, including weak harvest conditions, and lower academic and government research demand offset growth in laboratory services.
- Operating income increased about 13%. Gross-margin gains and lower restructuring charges helped; higher R&D investment and increased acquisition-related and contingent-consideration costs partly offset improvement.
- Continuing-operations operating cash flow increased by $59.9 million. Cash rose to $359.3 million from $237.9 million, while total debt increased modestly year over year.
- Fiscal 2016 included $5.1 million of net restructuring charges. The company also recorded a $16.2 million gain from changes in the fair value of contingent consideration as a non-cash operating cash-flow reconciliation item.
Outlook, management commentary, risks and unusual items
- Management expected fiscal 2017 capital expenditures to be similar to fiscal 2016 and said it planned to continue strong R&D investment. No quantified revenue or earnings guidance is provided in the filing.
- Management expected approximately $4.5 million of pension and postretirement-plan income in fiscal 2017, excluding any mark-to-market adjustment; such adjustments depend on market conditions and actuarial assumptions. It expected no significant future operating or cash-flow impact from fiscal 2016 restructuring actions.
- The planned Medical Imaging sale to Varian was for approximately $276 million in cash plus specified assumed liabilities. Closing was expected no earlier than April 2017, subject to customary conditions; the agreement included a possible termination fee of up to $22.1 million. This was not a completed fiscal 2016 sale.
- After year-end, the company completed its acquisition of Tulip Diagnostics for $125 million net of acquired cash, with up to $25 million of additional contingent consideration treated as compensation expense.
- Key risks include reliance on global markets and government funding, foreign-exchange exposure, product-development and acquisition execution, regulatory and product-liability exposure, limited-source suppliers, debt covenants and interest-rate exposure, and potential impairment of substantial goodwill and intangible assets. Informatics was identified as at increased impairment risk amid weakness and competition; management did not expect a material impairment based on its assumptions.
- Environmental remediation accruals were $9.9 million. Management said ordinary-course legal contingencies were not expected to materially adversely affect the financial statements, while noting outcomes remain uncertain. China and Singapore tax holidays contributed to a low 11.6% continuing-operations effective tax rate; the China holiday was scheduled to expire in fiscal 2017.
Important facts for investors to verify
- Confirm the issuer and ticker: this source is PerkinElmer, Inc. (PKI), and the stated period is fiscal 2016, not a standalone Q4 filing.
- Assess organic and constant-currency growth, including the 52-week versus 53-week period comparison and the discontinued Medical Imaging business.
- Track Diagnostics growth and Discovery & Analytical Solutions recovery, especially environmental/food demand, research funding and OneSource services.
- Verify completion and final proceeds of the Varian Medical Imaging transaction, and the financial impact of the subsequent Tulip acquisition.
- Monitor contingent consideration (recorded at $63.2 million, with potential acquisition payments up to $84.6 million), goodwill impairment assumptions, tax-holiday expirations and pension remeasurement effects.
- Review cash availability by jurisdiction, debt maturities and covenants, and whether buybacks and dividends remain supported by operating cash flow.